{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "serious-association",
   "metadata": {},
   "outputs": [],
   "source": [
    "from metakb.query import Query\n",
    "\n",
    "q = Query(uri=\"bolt://localhost:7687\", credentials=(\"neo4j\", \"admin\"))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "serious-hello",
   "metadata": {},
   "outputs": [
    {
     "ename": "AttributeError",
     "evalue": "'Query' object has no attribute 'find_node'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "\u001b[0;32m<timed eval>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n",
      "\u001b[0;31mAttributeError\u001b[0m: 'Query' object has no attribute 'find_node'"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "q.find_node('Evidence', 'civic:eid2997')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "classified-partnership",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CPU times: user 900 µs, sys: 790 µs, total: 1.69 ms\n",
      "Wall time: 6.94 ms\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<Record n=<Node id=1264 labels=frozenset({'Evidence'}) properties={'description': 'Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test', 'id': 'civic:eid2997', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>>"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%%time\n",
    "q.find_node_by_id(\"civic:eid2997\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "fresh-swiss",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<Record n=<Node id=656 labels=frozenset({'Therapy'}) properties={'id': 'ncit:C66940'}>>\n",
      "Therapy\n"
     ]
    }
   ],
   "source": [
    "x = q.find_node_by_id(\"ncit:C66940\")\n",
    "labels = x[0].labels\n",
    "label, *_ = labels\n",
    "print(x)\n",
    "print(label)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "ideal-suffering",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Record type='HAS_OBJECT'>"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "q.find_relationship('TherapeuticResponse', 'Therapy')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "israeli-promotion",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "earned-parks",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<Node id=656 labels=frozenset({'Therapy'}) properties={'id': 'ncit:C66940'}>\n",
      "Therapy\n",
      "ncit:C66940\n",
      "\n",
      "HAS_OBJECT\n",
      "\n",
      "<Record n1=<Node id=3350 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_resistance_to', 'variation_origin': 'somatic', '_id': 'proposition:787'}>>\n",
      "\n",
      "<Record n1=<Node id=3107 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:711'}>>\n",
      "\n",
      "<Record n1=<Node id=2919 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:678'}>>\n",
      "\n",
      "<Record n1=<Node id=2411 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:569'}>>\n",
      "\n",
      "<Record n1=<Node id=2409 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:568'}>>\n",
      "\n",
      "<Record n1=<Node id=2332 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:543'}>>\n",
      "\n",
      "<Record n1=<Node id=1224 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:237'}>>\n",
      "\n",
      "<Record n1=<Node id=1213 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:235'}>>\n",
      "\n",
      "<Record n1=<Node id=851 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:145'}>>\n",
      "\n",
      "<Record n1=<Node id=748 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:125'}>>\n",
      "\n",
      "<Record n1=<Node id=744 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:124'}>>\n",
      "\n",
      "<Record n1=<Node id=657 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:111'}>>\n",
      "\n"
     ]
    }
   ],
   "source": [
    "x = q.find_node_by_id(\"ncit:C66940\")[0]\n",
    "labels = x.labels\n",
    "label, *_ = labels\n",
    "print(x)\n",
    "print(label)\n",
    "print(x.get('id'))\n",
    "print()\n",
    "\n",
    "r = q.find_relationship('TherapeuticResponse', label)\n",
    "print(r.get('type'))\n",
    "print()\n",
    "\n",
    "n = q.get_node_from_relationship('TherapeuticResponse', label, x.get('id'), r.get('type'))\n",
    "for node in n:\n",
    "    print(node)\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "expected-bidding",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['proposition:787',\n",
       " 'proposition:711',\n",
       " 'proposition:678',\n",
       " 'proposition:569',\n",
       " 'proposition:568',\n",
       " 'proposition:543',\n",
       " 'proposition:237',\n",
       " 'proposition:235',\n",
       " 'proposition:145',\n",
       " 'proposition:125',\n",
       " 'proposition:124',\n",
       " 'proposition:111']"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[tr[0].get('_id') for tr in q.find_propositions_from_id('ncit:C66940')]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "mechanical-passion",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<Record n1=<Node id=3350 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_resistance_to', 'variation_origin': 'somatic', '_id': 'proposition:787'}>>,\n",
       " <Record n1=<Node id=3107 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:711'}>>,\n",
       " <Record n1=<Node id=2919 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:678'}>>,\n",
       " <Record n1=<Node id=2411 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:569'}>>,\n",
       " <Record n1=<Node id=2409 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:568'}>>,\n",
       " <Record n1=<Node id=2332 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:543'}>>,\n",
       " <Record n1=<Node id=1224 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:237'}>>,\n",
       " <Record n1=<Node id=1213 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:235'}>>,\n",
       " <Record n1=<Node id=851 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:145'}>>,\n",
       " <Record n1=<Node id=748 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:125'}>>,\n",
       " <Record n1=<Node id=744 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:124'}>>,\n",
       " <Record n1=<Node id=657 labels=frozenset({'Proposition', 'TherapeuticResponse'}) properties={'predicate': 'predicts_sensitivity_to', 'variation_origin': 'somatic', '_id': 'proposition:111'}>>]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[tr for tr in q.find_propositions_from_id('ncit:C66940')]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "sized-investing",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "productive-valley",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<Record e=<Node id=3351 labels=frozenset({'Evidence'}) properties={'description': 'Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).', 'id': 'civic:eid1863', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=3365 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.', 'id': 'civic:eid2163', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=2921 labels=frozenset({'Evidence'}) properties={'description': 'In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.', 'id': 'civic:eid1747', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=2412 labels=frozenset({'Evidence'}) properties={'description': 'Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with afatinib suppressed EGFR phosphorylation of L858R+L797S, and caused complete inhibition of phosphorylation of L858R+L718V and L858R+L718Q EGFR mutants.', 'id': 'civic:eid8074', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=2410 labels=frozenset({'Evidence'}) properties={'description': 'Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with afatinib suppressed EGFR phosphorylation of L858R+L797S, and caused complete inhibition of phosphorylation of L858R+L718V and L858R+L718Q EGFR mutants. Mice with EGFR L858R osimertinib-resistant tumours were treated with erlotinib or afatinib. Of twelve osimertinib-resistant tumours that responded to afatinib treatment, 7 had the C797S mutation and 4 had the L718Q mutation. Comparison of growth rates before and after being switched to erlotinib or afatinib treatment showed that both C797S and L718Q mutant tumours had a negative growth rate when treated with afatinib, suggesting sensitivity.', 'id': 'civic:eid8071', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=2334 labels=frozenset({'Evidence'}) properties={'description': 'In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.', 'id': 'civic:eid1748', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=1226 labels=frozenset({'Evidence'}) properties={'description': 'A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G776L (Case 2 in the paper) achieved a partial response after two months of afatinib (50 mg/day). The time to progression of this single agent was four months. The patient was also noted to have a EGFR kinase domain (exon 21: p.Ala859Thr) mutation.', 'id': 'civic:eid1889', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=1215 labels=frozenset({'Evidence'}) properties={'description': 'In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.', 'id': 'civic:eid1746', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=855 labels=frozenset({'Evidence'}) properties={'description': 'A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutation positive patients (n=308; exon 19 deletion and L858R mutation) treated with afatinib, as compared to patients treated with standard chemotherapy (cisplatin plus pemetrexed).', 'id': 'civic:eid2541', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=1264 labels=frozenset({'Evidence'}) properties={'description': 'Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test', 'id': 'civic:eid2997', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=1184 labels=frozenset({'Evidence'}) properties={'description': 'In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.', 'id': 'civic:eid883', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>>,\n",
       " <Record e=<Node id=658 labels=frozenset({'Evidence'}) properties={'description': 'Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with afatinib suppressed EGFR phosphorylation of L858R+C797S, and caused complete inhibition of phosphorylation of L858R+L718V and L858R+L718Q EGFR mutants. Mice with EGFR L858R osimertinib-resistant tumours were treated with erlotinib or afatinib. Of twelve osimertinib-resistant tumours that responded to afatinib treatment, 7 had the C797S mutation and 4 had the L718Q mutation. Comparison of growth rates before and after being switched to erlotinib or afatinib treatment showed that both C797S and L718Q mutant tumours had a negative growth rate when treated with afatinib, suggesting sensitivity.', 'id': 'civic:eid8070', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>>]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "propositions = [tr for tr in q.find_propositions_from_id('ncit:c66940')]\n",
    "q.find_evidence_from_propositions(propositions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "strategic-fighter",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<Record n=<Node id=655 labels=frozenset({'TherapyDescriptor'}) properties={'alternate_labels': \"['BIBW2992', 'BIBW 2992', '(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide']\", 'label': 'Afatinib', 'id': 'civic:tid146'}>>]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "q.find_node_by_label('afatinib')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "great-substance",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<Node id=26 labels=frozenset({'DiseaseDescriptor'}) properties={'label': 'Lung Non-small Cell Carcinoma', 'id': 'civic:did8'}>\n",
      "civic:did8\n",
      "DiseaseDescriptor\n",
      "\n",
      "HAS_DISEASE\n",
      "\n",
      "[<Node id=3889 labels=frozenset({'Evidence'}) properties={'description': 'In a metastatic EML4-ALK rearranged non-small cell lung carcinoma patient harboring ALK C1156Y (a known crizotinib resistance mutation) and ALK L1198F co-mutations, ALK L1198F was associated with resensitization to crizotinib monotherapy. After the patient developed ALK C1156Y mutation and became resistant to crizotinib, the patient underwent complex therapy regimens (including ceritinib, AUY922, standard chemotherapy , and 8 months of lorlatinib treatment); subsequently, a secondary mutation, ALK L1198F mutation, was identified. Upon reintroduction of crizotinib, the patient had a clinically significant radiologic response for almost 6 months. In an in vitro study, a Ba/F3 cell line expressing the L1198F mutation in the ALK portion of the EML4-ALK fusion protein demonstrated increased sensitivity to crizotinib treatment, as compared to cells expressing the EML4-ALK fusion protein. Sensitivity was determined by assessing cell-survival (IC50: 0.4 nM) and ALK auto-phosphorylation.', 'id': 'civic:eid4782', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=3878 labels=frozenset({'Evidence'}) properties={'description': 'Cells expressing EGFR harboring the S768N mutation were resistant to erlotinib treatment of up to 3uM, as measured using an in vitro fibril formation assay. This contrasts with cells expressing the L858R mutant conferring erlotinib sensitivity, where fibril formation was observed at concentrations of erlotinib as low as 30nM. In an in vitro study, a MCF-7 cell line expressing EGFR A767_V769dup mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing YFP signal-EGFR relocation.', 'id': 'civic:eid4272', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3876 labels=frozenset({'Evidence'}) properties={'description': 'The S768N mutation was first reported in a cohort of African American patients with non-small cell lung cancer (NSCLC).  Classical EGFR mutations such as the L858R mutation and exon 19 deletions, found in 10-15% of patients in the general population and 40-50% of East Asian patients, occur at a much lower frequency in African American patients.  For example, in a study of 53 African American NSCLC patients classical EGFR mutations were undetected.', 'id': 'civic:eid4271', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=3871 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a PC-9 cell line expressing BRAF G469A mutation demonstrated decreased sensitivity to erlotinib treatment compared to PC-9 cells expressing BRAF wild-type. Sensitivity was determined by performing cell growth-inhibition assays.', 'id': 'civic:eid4184', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3838 labels=frozenset({'Evidence'}) properties={'description': 'Case report of a patient with HCC and NSCLC (only NSCLC harboring the BRAF G469V mutation). Sorafenib at standard dosage led to a partial response in the primary lesion of the lung, complete response of the metastasis in the contralateral lung, and stability of HCC.', 'id': 'civic:eid1939', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=3784 labels=frozenset({'Evidence'}) properties={'description': 'In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony formation (P = 0.0004) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment was rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, siRNA facilitated depletion of ABL1 expression resulted in significantly increased cytotoxicity (P < 0.004) with no significant change in H2126 or Beas-2B lines for 2/3 siRNAs supporting ABL1 as the primary drug target. Significant tumor reduction was observed in murine NSCLC xenografts of the H1915 cell line treated with imatinib compared to vehicle treatment (P = 0.0016). No change in tumor growth was observed in xenografts of the H650 cell line containing a wildtype ABL1 locus. In both in vitro and in vivo experiments, doxycycline-inducible expression of drug-resistant ABL1-T315I rescued imatinib-mediated inhibitory effects supporting the specificity of drug responses.', 'id': 'civic:eid6376', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3758 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing a S1986Y mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 125 nM), as compared to Ba/F3 cells expressing EZR-ROS1 fusion (IC50: 43 nM). Resistance was determined by assessing cell viability, ROS1, AKT, ERK and S6 phosphorylation.', 'id': 'civic:eid4806', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3752 labels=frozenset({'Evidence'}) properties={'description': 'In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony formation (P < 0.001) and MTT assay, which tests for NADH activity (P = 1.09 x 10^5), with dasatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment could be rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, a significant increased in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.005) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target.', 'id': 'civic:eid4787', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3689 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 47 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4468', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3666 labels=frozenset({'Evidence'}) properties={'description': 'In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. The patient (M, 80, smoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 6.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.', 'id': 'civic:eid4231', 'evidence_level': 'civic.evidence_level:C', 'direction': 'does_not_support'}>, <Node id=3504 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid269', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3422 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a MCF-7 cell line expressing EGFR P848L demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors). Sensitivity was determined by assessing AKT phosphorylation.', 'id': 'civic:eid4281', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3395 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a MCF-7 cell line expressing EGFR L858R and T790M co-mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing YFP signal-EGFR relocation.', 'id': 'civic:eid3809', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3393 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a NCI-H1975 cell line expressing EGFR L858R and EGFR T790M co-mutation, EGFR T790M was associated with reduced sensitivity to erlotinib treatment compared to QG56 cells expressing EGFR wild-type. Sensitivity was determined by assessing cell viability (mean IC50 of erlotinib for cells expressing EGFR L858R and EGFR T790M co-mutations was 4.3 �M vs. 8.9 �M for EGFR wild-type expressing cells).', 'id': 'civic:eid3808', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3391 labels=frozenset({'Evidence'}) properties={'description': 'In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.', 'id': 'civic:eid3807', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=3390 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR S752_I759del demonstrated increased sensitivity to erlotinib treatment (IC50=33nM), comparable to Ba/F3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=16nM). Sensitivity was determined by assessing IL-3 independent cell survival.', 'id': 'civic:eid3801', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3368 labels=frozenset({'Evidence'}) properties={'description': 'In a prospective study (NCT01802632) of 253 locally advanced or metastatic, non-small cell lung cancer patients, patients with EGFR T790M mutations treated with osimertinib were associated with improved progression free survival (9.6mo, 95% CI:8.3-not reached vs. 2.8mo, 95% CI: 2.4-4.3), improved objective response rate (61% (78/127), 95% CI: 52-70 vs. 21% (37/61), 95% CI:12-34) and improved disease control rate (95% (121/127), 95% CI:90-98 vs. 61%, (37/61), 95% CI: 47-73), as compared to patients that did not harbor EGFR T790M mutations.', 'id': 'civic:eid2166', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=3367 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib.', 'id': 'civic:eid2165', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3365 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.', 'id': 'civic:eid2163', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3364 labels=frozenset({'Evidence'}) properties={'description': 'The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 μmol/L).\\nIn an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib.', 'id': 'civic:eid2162', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3362 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model', 'id': 'civic:eid2160', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3357 labels=frozenset({'Evidence'}) properties={'description': 'Case report of a patient with NSCLC and BRAF G469R mutation who showed a dramatic response to sorafenib.', 'id': 'civic:eid1938', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=3351 labels=frozenset({'Evidence'}) properties={'description': 'Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).', 'id': 'civic:eid1863', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=3348 labels=frozenset({'Evidence'}) properties={'description': 'Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.', 'id': 'civic:eid1592', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>, <Node id=3334 labels=frozenset({'Evidence'}) properties={'description': 'This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.', 'id': 'civic:eid965', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=3333 labels=frozenset({'Evidence'}) properties={'description': 'Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.', 'id': 'civic:eid963', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3331 labels=frozenset({'Evidence'}) properties={'description': 'CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.', 'id': 'civic:eid762', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3329 labels=frozenset({'Evidence'}) properties={'description': 'In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.', 'id': 'civic:eid646', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=3322 labels=frozenset({'Evidence'}) properties={'description': 'In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.', 'id': 'civic:eid278', 'evidence_level': 'civic.evidence_level:E', 'direction': 'supports'}>, <Node id=3284 labels=frozenset({'Evidence'}) properties={'description': 'Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. in May 2016, after receiving a negative reply from  the  FDA’s  Oncologic  Drugs  Advisory  Committee, \\nwhich voted 12–1 against the accelerated approval of rociletinib, Clovis Oncology decided to end the development of \\nrociletinib.\\nIn this review, the wide-ranging aspects of the evolution of EGFR-TKIs were collected, with a special focus on rociletinib.', 'id': 'civic:eid5709', 'evidence_level': 'civic.evidence_level:B', 'direction': 'does_not_support'}>, <Node id=3249 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK L1152P co-mutation, demonstrated resistance to crizotinib treatment compared to Ba/F3 cells expressing EML4-ALK fusion. Resistance was determined by assessing cell viability.', 'id': 'civic:eid4613', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3108 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor.', 'id': 'civic:eid2164', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3106 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 μmol/L for all three cell lines).', 'id': 'civic:eid2161', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3094 labels=frozenset({'Evidence'}) properties={'description': 'Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).', 'id': 'civic:eid1867', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>, <Node id=3081 labels=frozenset({'Evidence'}) properties={'description': 'This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.', 'id': 'civic:eid966', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=3073 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid266', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=3067 labels=frozenset({'Evidence'}) properties={'description': 'In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.', 'id': 'civic:eid240', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=3064 labels=frozenset({'Evidence'}) properties={'description': 'The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.', 'id': 'civic:eid238', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>, <Node id=2971 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, the HCC364 cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability, apoptosis and colony formation.', 'id': 'civic:eid3761', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2810 labels=frozenset({'Evidence'}) properties={'description': 'The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\\nWithin the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months).', 'id': 'civic:eid5958', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=2534 labels=frozenset({'Evidence'}) properties={'description': 'In a genetic screen of 87 lung cancer cell lines, one MEK-dependent cell line HCC364 contained a BRAF-V600E mutation. In growth assays, the MEK inhibitor PD-0325901 reduced proliferation in growth assays of the HCC364 cell line (IC50=3.2 nmol/L). Additionally, cells exposed to PD-0325901 exhibited an increase in apoptosis, as measured by induction of PARP cleavage.', 'id': 'civic:eid2143', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2444 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid270', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2439 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid268', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2429 labels=frozenset({'Evidence'}) properties={'description': 'In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.', 'id': 'civic:eid91', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=2386 labels=frozenset({'Evidence'}) properties={'description': 'A patient with ROS1 fusion-positive NSCLC was treated with crizotinib. After tumor progression, a repeat biopsy revealed ROS1 G2032R mutation.\\nThe patient subsequently enrolled in the phase I repotrectinib trial. A confirmed PR (−36.6%) was achieved with a duration of response of 7.4 months.\\nPharmacokinetic analyses revealed that the Ctrough (425 nmol/L) was above the IC90 (100 nmol/L) needed to inhibit ROS1G2032R Ba/F3 cell proliferation.', 'id': 'civic:eid7687', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=2378 labels=frozenset({'Evidence'}) properties={'description': 'The G719S mutation was found in a 50-year-old female never smoker with advanced adenocarcinoma of the lung. One month after the end of chemotherapy, , she started erlotinib at 150 mg/d. At the first computer tomography scan evaluation, performed 2 months later, disease reduction of multiple primary lung and nodal lesions was evident. Brain metastases were stable. The patient is still on treatment after 4 months.', 'id': 'civic:eid6040', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=2370 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing CD74-ROS1 fusion (a known sensitizing alteration to crizotinib) and a ROS1 G2032R co-mutation demonstrated resistance to crizotinib treatment (1,192 nmol/L vs. 18.4 nmol/L) compared to Ba/F3 cells expressing CD74-ROS1 fusion. Resistance was determined by assessing cell viability.', 'id': 'civic:eid4615', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2360 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a NIH-3T3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment compared to NIH-3T3 cells expressing EGFR wild-type. Sensitivity was determined by assessing anchorage-independent growth (growth of cells expressing EGFR G719S was inhibited by 100 nM of erlotinib, whereas growth of cells expressing EGFR wild-type was inhibited by >1 �M of erlotinib).', 'id': 'civic:eid4191', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2301 labels=frozenset({'Evidence'}) properties={'description': 'In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib \\nROS1 resistance mutations were identified in 9/17 (53%) specimens. These included G2032R (41%), D2033N (6%), and S1986F (6%).\\nG2032R is thought to result in steric hindrance with crizotinib, while D2033N leads to a reorientation of neighboring residues in front of the ATP binding pocket interacting with crizotinib and loss of a key electrostatic interaction between D2033 and crizotinib. ROS1 S1986F has been purported to confer resistance by impacting the positioning of the glycine-rich loop at the end of the alpha-C helix.', 'id': 'civic:eid7684', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=2242 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing a G2032R mutation in the ROS1 portion of the  EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 1287 nM), as compared to Ba/F3 cells expressing EZR-ROS1 fusion (IC50: 43 nM). Resistance was determined by assessing cell viability, ROS1, AKT, ERK and S6 phosphorylation.', 'id': 'civic:eid4616', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2240 labels=frozenset({'Evidence'}) properties={'description': 'In a phase 1 study (NCT00585195), a stage IIIA pulmonary adenocarcinoma patient with acquired crizotinib resistance harbored a CD74-ROS1 gene rearrangement (a known sensitizing alteration to crizotinib) and a ROS1 G2032R co-mutation. The ROS1 G2032R tumor was reported to be refractory to 12-month crizotinib treatment. The patient was treated with 8 cycles of standard chemotherapy prior to crizotinib treatment. In an in vitro study, a Ba/F3 cell line expressing CD74-ROS1 fusion (a known sensitizing alteration to crizotinib) and a ROS1 G2032R co-mutation demonstrated resistance to crizotinib treatment (IC50: 353.64 nmol/L vs. 2.76 nmol/L) compared to Ba/F3 cells expressing CD74-ROS1 fusion. Resistance was determined by assessing cell viability and ROS1 auto-phosphorylation.', 'id': 'civic:eid4614', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=2213 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L838V and EGFR L858R expressing cells were 160 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4280', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2208 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR G719S and EGFR L858R expressing cells were 16 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4190', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2059 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK L1198P co-mutation, demonstrated resistance to crizotinib treatment compared to Ba/F3 cells expressing EML4-ALK fusion. Resistance was determined by assessing cell viability and ALK auto-phosphorylation.', 'id': 'civic:eid4626', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=29 labels=frozenset({'Evidence'}) properties={'description': 'Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.', 'id': 'civic:eid33', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=65 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid271', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=230 labels=frozenset({'Evidence'}) properties={'description': \"S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood. In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy.\", 'id': 'civic:eid2906', 'evidence_level': 'civic.evidence_level:C', 'direction': 'does_not_support'}>, <Node id=310 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR A864T and EGFR L858R expressing cells were 49 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4495', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=313 labels=frozenset({'Evidence'}) properties={'description': 'In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplications in exon 20 (n=25). Patients with EGFR deletions in exon 19 or L858R mutations were associated with an improved response to erlotinib or gefitinib with partial or complete response (74.1% vs. 16.5%, P<0.001) when compared to wildtype EGFR patients. Additionally, tumors with EGFR mutations in L858R or deletions in exon 19 were associated with increased overall survival (19.6mo vs. 10.4mo) compared to wildtype (all patients were treated with either erlotinib or gefitinib).', 'id': 'civic:eid4514', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=414 labels=frozenset({'Evidence'}) properties={'description': 'In this systematic pubmed search, EGFR variants associated with Response to EGFR-directed therapy were summarized.\\nOne Patient with an EGFR R832L Mutation achieved stable disease with an EGFR Inhibitor.\\nMore specific Information are not availabe neither in this publication, nor in the referenced original document: https://ascopubs.org/doi/abs/10.1200/jco.2011.29.18_suppl.cra7506', 'id': 'civic:eid7368', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=502 labels=frozenset({'Evidence'}) properties={'description': 'An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation.', 'id': 'civic:eid964', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=585 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a NIH3T3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment comparable to NIH3T3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors). Sensitivity was determined by assessing EGFR auto-phosphorylation.', 'id': 'civic:eid4185', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=591 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a MCF-7 cell line expressing EGFR A859T demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors). Sensitivity was determined by assessing AKT phosphorylation.', 'id': 'civic:eid4296', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=644 labels=frozenset({'Evidence'}) properties={'description': 'In a multicenter phase II trial in Korea, patients with NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R, T790M, and exon 20 insertion were treated with osimertinib. Patients who were previously treated with other EGFR inhibitors were excluded.\\nThirty-seven patients were enrolled. Among patients, 61% received osimertinib as first-line therapy. \\nThe mutations were G719X (n=19), L861Q (n=9), S768I (n=8) and others (n=4).\\nThe objective response rate was 50% (18/36). Median progression-free survival was 8.2 months and median overall survival was not reached. The median duration of response was 11.2 months.', 'id': 'civic:eid7858', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=647 labels=frozenset({'Evidence'}) properties={'description': 'In a multicenter phase II trial in Korea, patients with NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R, T790M, and exon 20 insertion were treated with osimertinib. Patients who were previously treated with other EGFR inhibitors were excluded.\\nThirty-seven patients were enrolled. Among patients, 61% received osimertinib as first-line therapy. \\nThe mutations were G719X (n=19), L861Q (n=9), S768I (n=8) and others (n=4).\\nThe objective response rate was 50% (18/36). Median progression-free survival was 8.2 months and median overall survival was not reached. The median duration of response was 11.2 months.', 'id': 'civic:eid7859', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=749 labels=frozenset({'Evidence'}) properties={'description': 'Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.', 'id': 'civic:eid968', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=853 labels=frozenset({'Evidence'}) properties={'description': 'In a study of 585 non-small cell lung cancer patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved response to afatinib for progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control.', 'id': 'civic:eid2540', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=855 labels=frozenset({'Evidence'}) properties={'description': 'A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutation positive patients (n=308; exon 19 deletion and L858R mutation) treated with afatinib, as compared to patients treated with standard chemotherapy (cisplatin plus pemetrexed).', 'id': 'civic:eid2541', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=859 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).', 'id': 'civic:eid2627', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=861 labels=frozenset({'Evidence'}) properties={'description': 'In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control.', 'id': 'civic:eid2630', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=902 labels=frozenset({'Evidence'}) properties={'description': 'On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.', 'id': 'civic:eid2994', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>, <Node id=950 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006�M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.', 'id': 'civic:eid4286', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=953 labels=frozenset({'Evidence'}) properties={'description': 'In a non-small cell lung cancer patient with an EGFR L858R mutation, EGFR L858R was reported to be refractory to 61-day crizotinib treatment.', 'id': 'civic:eid4288', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=1029 labels=frozenset({'Evidence'}) properties={'description': 'The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.', 'id': 'civic:eid4860', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=1147 labels=frozenset({'Evidence'}) properties={'description': 'In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.', 'id': 'civic:eid17', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=1149 labels=frozenset({'Evidence'}) properties={'description': 'Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.', 'id': 'civic:eid40', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1151 labels=frozenset({'Evidence'}) properties={'description': 'Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.', 'id': 'civic:eid41', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1186 labels=frozenset({'Evidence'}) properties={'description': 'A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.', 'id': 'civic:eid885', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=1244 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.', 'id': 'civic:eid2626', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1247 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1781 cells (EGFR wild-type) and NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to neratinib (IC50: 0.0049umol/L vs. 0.085umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug erlotinib (IC50: 0.031umol/L vs. wildtype >1umol/L).', 'id': 'civic:eid2628', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1249 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.', 'id': 'civic:eid2629', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1253 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.', 'id': 'civic:eid2631', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1254 labels=frozenset({'Evidence'}) properties={'description': 'In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.', 'id': 'civic:eid2632', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=1259 labels=frozenset({'Evidence'}) properties={'description': 'EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.In an in vitro study using PC9 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 11.0-12.0 nmol/L vs 61.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).', 'id': 'civic:eid2633', 'evidence_level': 'civic.evidence_level:D'}>, <Node id=1264 labels=frozenset({'Evidence'}) properties={'description': 'Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test', 'id': 'civic:eid2997', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>, <Node id=1278 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a PC-9 cell line expressing NRAS Q61K mutation demonstrated decreased sensitivity to erlotinib treatment compared to PC-9 cells expressing NRAS wild-type. Sensitivity was determined by performing cell growth-inhibition assays.', 'id': 'civic:eid3839', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1291 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR E746_S752insV demonstrated increased sensitivity to erlotinib treatment (IC50=25nM), comparable to Ba/F3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=16nM). Sensitivity was determined by IL-3 independent cell survival.', 'id': 'civic:eid4232', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1294 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.', 'id': 'civic:eid4284', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1295 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.', 'id': 'civic:eid4285', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1297 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.', 'id': 'civic:eid4287', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1545 labels=frozenset({'Evidence'}) properties={'description': '3 patients with stage IV non small cell lung adenocarcinoma with G719A mutation were given erlotinib. 1 patient was alive at end of study with progression free survival (PFS) of 27.2 months and overall survival (OS) or 42.4 months, and 2 patients had PFS of 1.3 and 2.1 months, and OS of 9.6 and 2.2 months, and were not alive at study end. In general G719 mutations were reported as having favorable response to tyrosine kinase inhibition in this study, although it was not as high as among exon 19 deletion and L858R mutations.', 'id': 'civic:eid4194', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=1550 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK F1174C co-mutation, demonstrated resistance to crizotinib treatment compared to Ba/F3 cells expressing EML4-ALK fusion. Resistance was determined by assessing cell viability.', 'id': 'civic:eid4430', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1556 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4496', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1591 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing S1986F mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 116 nM), as compared to Ba/F3 cells expressing EZR-ROS1 fusion (IC50: 43 nM). Resistance was determined by assessing cell viability, ROS1, AKT, ERK and S6 phosphorylation.', 'id': 'civic:eid4807', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1630 labels=frozenset({'Evidence'}) properties={'description': 'In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib \\nROS1 resistance mutations were identified in 9/17 (53%) specimens. These included G2032R (41%), D2033N (6%), and S1986F (6%).\\nG2032R is thought to result in steric hindrance with crizotinib,16 while D2033N leads to a reorientation of neighboring residues in front of the ATP binding pocket interacting with crizotinib and loss of a key electrostatic interaction between D2033 and crizotinib. ROS1 S1986F has been purported to confer resistance by impacting the positioning of the glycine-rich loop at the end of the alpha-C helix.', 'id': 'civic:eid7686', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=1703 labels=frozenset({'Evidence'}) properties={'description': 'In a study of 889 non-small cell lung cancer patients, mutations in the EGFR gene was observed in 11.1% of patients (58 of 518 sequenced). Patients with an EGFR mutation were associated with an improved response to erlotinib over placebo treatment (HR:0.10, 95% CI:0.04-0.25, P<0.0001); patients wildtype for EGFR also saw an improved response to erlotinib over placebo treatment (HR:0.78, 95% CI:0.63-0.96, P=0.0185).', 'id': 'civic:eid4195', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>, <Node id=1721 labels=frozenset({'Evidence'}) properties={'description': 'In a phase 2 study (NCT0093245), a stage IV non-small cell lung cancer patient with acquired crizotinib resistance harbored an EML4-ALK gene rearrangement (a known sensitizing alteration to crizotinib) and an ALK F1174V co-mutation. The ALK F1174V tumor was reported to be refractory to 21-month crizotinib treatment. The patient was treated with erlotinib, 6 cycles of standard chemotherapy, pemetrexed maintenance and then crizotinib..', 'id': 'civic:eid4473', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=1772 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid267', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1887 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 21 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4197', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1967 labels=frozenset({'Evidence'}) properties={'description': 'A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. Sequencing of circulating cell-free DNA showed EGFR L858R, an acquired novel EGFR M766Q mutation in exon 20, and no evidence of EGFR T790M.', 'id': 'civic:eid7388', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>, <Node id=1970 labels=frozenset({'Evidence'}) properties={'description': 'L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to various EGFR inhibitors.\\nModeling suggested that EGFR M766Q could disrupt osimertinib binding. L858R/M766Q double-mutant cells were 12-fold more resistant to osimertinib, and more than 250-fold more resistant to erlotinib and afatinib, as compared to L858R-mutant cells. In contrast, double-mutant cells remained sensitive to neratinib and poziotinib at clinically relevant doses (IC50, 4.3 and 1.3 nM, respectively).', 'id': 'civic:eid7389', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=1974 labels=frozenset({'Evidence'}) properties={'description': 'L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to various EGFR inhibitors.\\nModeling suggested that EGFR M766Q could disrupt osimertinib binding. L858R/M766Q double-mutant cells were 12-fold more resistant to osimertinib, and more than 250-fold more resistant to erlotinib and afatinib, as compared to L858R-mutant cells. In contrast, double-mutant cells remained sensitive to neratinib and poziotinib at clinically relevant doses (IC50, 4.3 and 1.3 nM, respectively).', 'id': 'civic:eid7390', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>, <Node id=2053 labels=frozenset({'Evidence'}) properties={'description': 'In a pulmonary undifferentiated non-small cell lung cancer patient harboring EGFR S784F mutation, EGFR S784F was reported to be resistant to erlotinib treatment. The patient was initially treated with standard chemotherapy, followed by erlotinib monotherapy, tumor progression was reported after 10 weeks of erlotinib treatment.', 'id': 'civic:eid4469', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>]\n"
     ]
    }
   ],
   "source": [
    "node = q.find_node_by_label('Lung Non-small Cell Carcinoma')[0][0]\n",
    "label, *_ = node.labels\n",
    "node_id = node.get('id')\n",
    "print(node)\n",
    "print(node_id)\n",
    "print(label)\n",
    "print()\n",
    "\n",
    "r = q.find_relationship('Evidence', label).get('type')\n",
    "print(r)\n",
    "print()\n",
    "\n",
    "e = q.find_evidence_from_descriptor(node_id, label, r)\n",
    "print(e)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "positive-yemen",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "103\n"
     ]
    }
   ],
   "source": [
    "print(len(e))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "patient-gazette",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<Node id=26 labels=frozenset({'DiseaseDescriptor'}) properties={'label': 'Lung Non-small Cell Carcinoma', 'id': 'civic:did8'}>\n",
      "<class 'neo4j.graph.Node'>\n"
     ]
    }
   ],
   "source": [
    "x = q.find_node_by_label(\"Lung Non-small Cell Carcinoma\")[0][0]\n",
    "print(x)\n",
    "print(type(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "aerial-wireless",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "skilled-ideal",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "coastal-understanding",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fundamental-washington",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "above-terminal",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<Node id=3889 labels=frozenset({'Evidence'}) properties={'description': 'In a metastatic EML4-ALK rearranged non-small cell lung carcinoma patient harboring ALK C1156Y (a known crizotinib resistance mutation) and ALK L1198F co-mutations, ALK L1198F was associated with resensitization to crizotinib monotherapy. After the patient developed ALK C1156Y mutation and became resistant to crizotinib, the patient underwent complex therapy regimens (including ceritinib, AUY922, standard chemotherapy , and 8 months of lorlatinib treatment); subsequently, a secondary mutation, ALK L1198F mutation, was identified. Upon reintroduction of crizotinib, the patient had a clinically significant radiologic response for almost 6 months. In an in vitro study, a Ba/F3 cell line expressing the L1198F mutation in the ALK portion of the EML4-ALK fusion protein demonstrated increased sensitivity to crizotinib treatment, as compared to cells expressing the EML4-ALK fusion protein. Sensitivity was determined by assessing cell-survival (IC50: 0.4 nM) and ALK auto-phosphorylation.', 'id': 'civic:eid4782', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=3878 labels=frozenset({'Evidence'}) properties={'description': 'Cells expressing EGFR harboring the S768N mutation were resistant to erlotinib treatment of up to 3uM, as measured using an in vitro fibril formation assay. This contrasts with cells expressing the L858R mutant conferring erlotinib sensitivity, where fibril formation was observed at concentrations of erlotinib as low as 30nM. In an in vitro study, a MCF-7 cell line expressing EGFR A767_V769dup mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing YFP signal-EGFR relocation.', 'id': 'civic:eid4272', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3876 labels=frozenset({'Evidence'}) properties={'description': 'The S768N mutation was first reported in a cohort of African American patients with non-small cell lung cancer (NSCLC).  Classical EGFR mutations such as the L858R mutation and exon 19 deletions, found in 10-15% of patients in the general population and 40-50% of East Asian patients, occur at a much lower frequency in African American patients.  For example, in a study of 53 African American NSCLC patients classical EGFR mutations were undetected.', 'id': 'civic:eid4271', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=3871 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a PC-9 cell line expressing BRAF G469A mutation demonstrated decreased sensitivity to erlotinib treatment compared to PC-9 cells expressing BRAF wild-type. Sensitivity was determined by performing cell growth-inhibition assays.', 'id': 'civic:eid4184', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3838 labels=frozenset({'Evidence'}) properties={'description': 'Case report of a patient with HCC and NSCLC (only NSCLC harboring the BRAF G469V mutation). Sorafenib at standard dosage led to a partial response in the primary lesion of the lung, complete response of the metastasis in the contralateral lung, and stability of HCC.', 'id': 'civic:eid1939', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=3784 labels=frozenset({'Evidence'}) properties={'description': 'In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony formation (P = 0.0004) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment was rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, siRNA facilitated depletion of ABL1 expression resulted in significantly increased cytotoxicity (P < 0.004) with no significant change in H2126 or Beas-2B lines for 2/3 siRNAs supporting ABL1 as the primary drug target. Significant tumor reduction was observed in murine NSCLC xenografts of the H1915 cell line treated with imatinib compared to vehicle treatment (P = 0.0016). No change in tumor growth was observed in xenografts of the H650 cell line containing a wildtype ABL1 locus. In both in vitro and in vivo experiments, doxycycline-inducible expression of drug-resistant ABL1-T315I rescued imatinib-mediated inhibitory effects supporting the specificity of drug responses.', 'id': 'civic:eid6376', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3758 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing a S1986Y mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 125 nM), as compared to Ba/F3 cells expressing EZR-ROS1 fusion (IC50: 43 nM). Resistance was determined by assessing cell viability, ROS1, AKT, ERK and S6 phosphorylation.', 'id': 'civic:eid4806', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3752 labels=frozenset({'Evidence'}) properties={'description': 'In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony formation (P < 0.001) and MTT assay, which tests for NADH activity (P = 1.09 x 10^5), with dasatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment could be rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, a significant increased in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.005) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target.', 'id': 'civic:eid4787', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3689 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 47 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4468', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3666 labels=frozenset({'Evidence'}) properties={'description': 'In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. The patient (M, 80, smoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 6.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.', 'id': 'civic:eid4231', 'evidence_level': 'civic.evidence_level:C', 'direction': 'does_not_support'}>,\n",
       " <Node id=3504 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid269', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3422 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a MCF-7 cell line expressing EGFR P848L demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors). Sensitivity was determined by assessing AKT phosphorylation.', 'id': 'civic:eid4281', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3395 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a MCF-7 cell line expressing EGFR L858R and T790M co-mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing YFP signal-EGFR relocation.', 'id': 'civic:eid3809', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3393 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a NCI-H1975 cell line expressing EGFR L858R and EGFR T790M co-mutation, EGFR T790M was associated with reduced sensitivity to erlotinib treatment compared to QG56 cells expressing EGFR wild-type. Sensitivity was determined by assessing cell viability (mean IC50 of erlotinib for cells expressing EGFR L858R and EGFR T790M co-mutations was 4.3 �M vs. 8.9 �M for EGFR wild-type expressing cells).', 'id': 'civic:eid3808', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3391 labels=frozenset({'Evidence'}) properties={'description': 'In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.', 'id': 'civic:eid3807', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=3390 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR S752_I759del demonstrated increased sensitivity to erlotinib treatment (IC50=33nM), comparable to Ba/F3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=16nM). Sensitivity was determined by assessing IL-3 independent cell survival.', 'id': 'civic:eid3801', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3368 labels=frozenset({'Evidence'}) properties={'description': 'In a prospective study (NCT01802632) of 253 locally advanced or metastatic, non-small cell lung cancer patients, patients with EGFR T790M mutations treated with osimertinib were associated with improved progression free survival (9.6mo, 95% CI:8.3-not reached vs. 2.8mo, 95% CI: 2.4-4.3), improved objective response rate (61% (78/127), 95% CI: 52-70 vs. 21% (37/61), 95% CI:12-34) and improved disease control rate (95% (121/127), 95% CI:90-98 vs. 61%, (37/61), 95% CI: 47-73), as compared to patients that did not harbor EGFR T790M mutations.', 'id': 'civic:eid2166', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=3367 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib.', 'id': 'civic:eid2165', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3365 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.', 'id': 'civic:eid2163', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3364 labels=frozenset({'Evidence'}) properties={'description': 'The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 μmol/L).\\nIn an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib.', 'id': 'civic:eid2162', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3362 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model', 'id': 'civic:eid2160', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3357 labels=frozenset({'Evidence'}) properties={'description': 'Case report of a patient with NSCLC and BRAF G469R mutation who showed a dramatic response to sorafenib.', 'id': 'civic:eid1938', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=3351 labels=frozenset({'Evidence'}) properties={'description': 'Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).', 'id': 'civic:eid1863', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=3348 labels=frozenset({'Evidence'}) properties={'description': 'Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.', 'id': 'civic:eid1592', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>,\n",
       " <Node id=3334 labels=frozenset({'Evidence'}) properties={'description': 'This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.', 'id': 'civic:eid965', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=3333 labels=frozenset({'Evidence'}) properties={'description': 'Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.', 'id': 'civic:eid963', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3331 labels=frozenset({'Evidence'}) properties={'description': 'CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.', 'id': 'civic:eid762', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3329 labels=frozenset({'Evidence'}) properties={'description': 'In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.', 'id': 'civic:eid646', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=3322 labels=frozenset({'Evidence'}) properties={'description': 'In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.', 'id': 'civic:eid278', 'evidence_level': 'civic.evidence_level:E', 'direction': 'supports'}>,\n",
       " <Node id=3284 labels=frozenset({'Evidence'}) properties={'description': 'Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. in May 2016, after receiving a negative reply from  the  FDA’s  Oncologic  Drugs  Advisory  Committee, \\nwhich voted 12–1 against the accelerated approval of rociletinib, Clovis Oncology decided to end the development of \\nrociletinib.\\nIn this review, the wide-ranging aspects of the evolution of EGFR-TKIs were collected, with a special focus on rociletinib.', 'id': 'civic:eid5709', 'evidence_level': 'civic.evidence_level:B', 'direction': 'does_not_support'}>,\n",
       " <Node id=3249 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK L1152P co-mutation, demonstrated resistance to crizotinib treatment compared to Ba/F3 cells expressing EML4-ALK fusion. Resistance was determined by assessing cell viability.', 'id': 'civic:eid4613', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3108 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor.', 'id': 'civic:eid2164', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3106 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 μmol/L for all three cell lines).', 'id': 'civic:eid2161', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3094 labels=frozenset({'Evidence'}) properties={'description': 'Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).', 'id': 'civic:eid1867', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>,\n",
       " <Node id=3081 labels=frozenset({'Evidence'}) properties={'description': 'This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.', 'id': 'civic:eid966', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=3073 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid266', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=3067 labels=frozenset({'Evidence'}) properties={'description': 'In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.', 'id': 'civic:eid240', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=3064 labels=frozenset({'Evidence'}) properties={'description': 'The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.', 'id': 'civic:eid238', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>,\n",
       " <Node id=2971 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, the HCC364 cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability, apoptosis and colony formation.', 'id': 'civic:eid3761', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2810 labels=frozenset({'Evidence'}) properties={'description': 'The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\\nWithin the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months).', 'id': 'civic:eid5958', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=2534 labels=frozenset({'Evidence'}) properties={'description': 'In a genetic screen of 87 lung cancer cell lines, one MEK-dependent cell line HCC364 contained a BRAF-V600E mutation. In growth assays, the MEK inhibitor PD-0325901 reduced proliferation in growth assays of the HCC364 cell line (IC50=3.2 nmol/L). Additionally, cells exposed to PD-0325901 exhibited an increase in apoptosis, as measured by induction of PARP cleavage.', 'id': 'civic:eid2143', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2444 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid270', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2439 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid268', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2429 labels=frozenset({'Evidence'}) properties={'description': 'In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.', 'id': 'civic:eid91', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=2386 labels=frozenset({'Evidence'}) properties={'description': 'A patient with ROS1 fusion-positive NSCLC was treated with crizotinib. After tumor progression, a repeat biopsy revealed ROS1 G2032R mutation.\\nThe patient subsequently enrolled in the phase I repotrectinib trial. A confirmed PR (−36.6%) was achieved with a duration of response of 7.4 months.\\nPharmacokinetic analyses revealed that the Ctrough (425 nmol/L) was above the IC90 (100 nmol/L) needed to inhibit ROS1G2032R Ba/F3 cell proliferation.', 'id': 'civic:eid7687', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=2378 labels=frozenset({'Evidence'}) properties={'description': 'The G719S mutation was found in a 50-year-old female never smoker with advanced adenocarcinoma of the lung. One month after the end of chemotherapy, , she started erlotinib at 150 mg/d. At the first computer tomography scan evaluation, performed 2 months later, disease reduction of multiple primary lung and nodal lesions was evident. Brain metastases were stable. The patient is still on treatment after 4 months.', 'id': 'civic:eid6040', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=2370 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing CD74-ROS1 fusion (a known sensitizing alteration to crizotinib) and a ROS1 G2032R co-mutation demonstrated resistance to crizotinib treatment (1,192 nmol/L vs. 18.4 nmol/L) compared to Ba/F3 cells expressing CD74-ROS1 fusion. Resistance was determined by assessing cell viability.', 'id': 'civic:eid4615', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2360 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a NIH-3T3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment compared to NIH-3T3 cells expressing EGFR wild-type. Sensitivity was determined by assessing anchorage-independent growth (growth of cells expressing EGFR G719S was inhibited by 100 nM of erlotinib, whereas growth of cells expressing EGFR wild-type was inhibited by >1 �M of erlotinib).', 'id': 'civic:eid4191', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2301 labels=frozenset({'Evidence'}) properties={'description': 'In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib \\nROS1 resistance mutations were identified in 9/17 (53%) specimens. These included G2032R (41%), D2033N (6%), and S1986F (6%).\\nG2032R is thought to result in steric hindrance with crizotinib, while D2033N leads to a reorientation of neighboring residues in front of the ATP binding pocket interacting with crizotinib and loss of a key electrostatic interaction between D2033 and crizotinib. ROS1 S1986F has been purported to confer resistance by impacting the positioning of the glycine-rich loop at the end of the alpha-C helix.', 'id': 'civic:eid7684', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=2242 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing a G2032R mutation in the ROS1 portion of the  EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 1287 nM), as compared to Ba/F3 cells expressing EZR-ROS1 fusion (IC50: 43 nM). Resistance was determined by assessing cell viability, ROS1, AKT, ERK and S6 phosphorylation.', 'id': 'civic:eid4616', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2240 labels=frozenset({'Evidence'}) properties={'description': 'In a phase 1 study (NCT00585195), a stage IIIA pulmonary adenocarcinoma patient with acquired crizotinib resistance harbored a CD74-ROS1 gene rearrangement (a known sensitizing alteration to crizotinib) and a ROS1 G2032R co-mutation. The ROS1 G2032R tumor was reported to be refractory to 12-month crizotinib treatment. The patient was treated with 8 cycles of standard chemotherapy prior to crizotinib treatment. In an in vitro study, a Ba/F3 cell line expressing CD74-ROS1 fusion (a known sensitizing alteration to crizotinib) and a ROS1 G2032R co-mutation demonstrated resistance to crizotinib treatment (IC50: 353.64 nmol/L vs. 2.76 nmol/L) compared to Ba/F3 cells expressing CD74-ROS1 fusion. Resistance was determined by assessing cell viability and ROS1 auto-phosphorylation.', 'id': 'civic:eid4614', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=2213 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L838V and EGFR L858R expressing cells were 160 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4280', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2208 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR G719S and EGFR L858R expressing cells were 16 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4190', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2059 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK L1198P co-mutation, demonstrated resistance to crizotinib treatment compared to Ba/F3 cells expressing EML4-ALK fusion. Resistance was determined by assessing cell viability and ALK auto-phosphorylation.', 'id': 'civic:eid4626', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=29 labels=frozenset({'Evidence'}) properties={'description': 'Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.', 'id': 'civic:eid33', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=65 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid271', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=230 labels=frozenset({'Evidence'}) properties={'description': \"S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood. In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy.\", 'id': 'civic:eid2906', 'evidence_level': 'civic.evidence_level:C', 'direction': 'does_not_support'}>,\n",
       " <Node id=310 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR A864T and EGFR L858R expressing cells were 49 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4495', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=313 labels=frozenset({'Evidence'}) properties={'description': 'In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplications in exon 20 (n=25). Patients with EGFR deletions in exon 19 or L858R mutations were associated with an improved response to erlotinib or gefitinib with partial or complete response (74.1% vs. 16.5%, P<0.001) when compared to wildtype EGFR patients. Additionally, tumors with EGFR mutations in L858R or deletions in exon 19 were associated with increased overall survival (19.6mo vs. 10.4mo) compared to wildtype (all patients were treated with either erlotinib or gefitinib).', 'id': 'civic:eid4514', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=414 labels=frozenset({'Evidence'}) properties={'description': 'In this systematic pubmed search, EGFR variants associated with Response to EGFR-directed therapy were summarized.\\nOne Patient with an EGFR R832L Mutation achieved stable disease with an EGFR Inhibitor.\\nMore specific Information are not availabe neither in this publication, nor in the referenced original document: https://ascopubs.org/doi/abs/10.1200/jco.2011.29.18_suppl.cra7506', 'id': 'civic:eid7368', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=502 labels=frozenset({'Evidence'}) properties={'description': 'An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation.', 'id': 'civic:eid964', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=585 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a NIH3T3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment comparable to NIH3T3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors). Sensitivity was determined by assessing EGFR auto-phosphorylation.', 'id': 'civic:eid4185', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=591 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a MCF-7 cell line expressing EGFR A859T demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors). Sensitivity was determined by assessing AKT phosphorylation.', 'id': 'civic:eid4296', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=644 labels=frozenset({'Evidence'}) properties={'description': 'In a multicenter phase II trial in Korea, patients with NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R, T790M, and exon 20 insertion were treated with osimertinib. Patients who were previously treated with other EGFR inhibitors were excluded.\\nThirty-seven patients were enrolled. Among patients, 61% received osimertinib as first-line therapy. \\nThe mutations were G719X (n=19), L861Q (n=9), S768I (n=8) and others (n=4).\\nThe objective response rate was 50% (18/36). Median progression-free survival was 8.2 months and median overall survival was not reached. The median duration of response was 11.2 months.', 'id': 'civic:eid7858', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=647 labels=frozenset({'Evidence'}) properties={'description': 'In a multicenter phase II trial in Korea, patients with NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R, T790M, and exon 20 insertion were treated with osimertinib. Patients who were previously treated with other EGFR inhibitors were excluded.\\nThirty-seven patients were enrolled. Among patients, 61% received osimertinib as first-line therapy. \\nThe mutations were G719X (n=19), L861Q (n=9), S768I (n=8) and others (n=4).\\nThe objective response rate was 50% (18/36). Median progression-free survival was 8.2 months and median overall survival was not reached. The median duration of response was 11.2 months.', 'id': 'civic:eid7859', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=749 labels=frozenset({'Evidence'}) properties={'description': 'Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.', 'id': 'civic:eid968', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=853 labels=frozenset({'Evidence'}) properties={'description': 'In a study of 585 non-small cell lung cancer patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved response to afatinib for progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control.', 'id': 'civic:eid2540', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=855 labels=frozenset({'Evidence'}) properties={'description': 'A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutation positive patients (n=308; exon 19 deletion and L858R mutation) treated with afatinib, as compared to patients treated with standard chemotherapy (cisplatin plus pemetrexed).', 'id': 'civic:eid2541', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=859 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).', 'id': 'civic:eid2627', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=861 labels=frozenset({'Evidence'}) properties={'description': 'In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control.', 'id': 'civic:eid2630', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=902 labels=frozenset({'Evidence'}) properties={'description': 'On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.', 'id': 'civic:eid2994', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>,\n",
       " <Node id=950 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006�M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.', 'id': 'civic:eid4286', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=953 labels=frozenset({'Evidence'}) properties={'description': 'In a non-small cell lung cancer patient with an EGFR L858R mutation, EGFR L858R was reported to be refractory to 61-day crizotinib treatment.', 'id': 'civic:eid4288', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=1029 labels=frozenset({'Evidence'}) properties={'description': 'The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.', 'id': 'civic:eid4860', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=1147 labels=frozenset({'Evidence'}) properties={'description': 'In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.', 'id': 'civic:eid17', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=1149 labels=frozenset({'Evidence'}) properties={'description': 'Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.', 'id': 'civic:eid40', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1151 labels=frozenset({'Evidence'}) properties={'description': 'Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.', 'id': 'civic:eid41', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1186 labels=frozenset({'Evidence'}) properties={'description': 'A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.', 'id': 'civic:eid885', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=1244 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.', 'id': 'civic:eid2626', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1247 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1781 cells (EGFR wild-type) and NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to neratinib (IC50: 0.0049umol/L vs. 0.085umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug erlotinib (IC50: 0.031umol/L vs. wildtype >1umol/L).', 'id': 'civic:eid2628', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1249 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.', 'id': 'civic:eid2629', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1253 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.', 'id': 'civic:eid2631', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1254 labels=frozenset({'Evidence'}) properties={'description': 'In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.', 'id': 'civic:eid2632', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=1259 labels=frozenset({'Evidence'}) properties={'description': 'EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.In an in vitro study using PC9 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 11.0-12.0 nmol/L vs 61.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).', 'id': 'civic:eid2633', 'evidence_level': 'civic.evidence_level:D'}>,\n",
       " <Node id=1264 labels=frozenset({'Evidence'}) properties={'description': 'Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test', 'id': 'civic:eid2997', 'evidence_level': 'civic.evidence_level:A', 'direction': 'supports'}>,\n",
       " <Node id=1278 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a PC-9 cell line expressing NRAS Q61K mutation demonstrated decreased sensitivity to erlotinib treatment compared to PC-9 cells expressing NRAS wild-type. Sensitivity was determined by performing cell growth-inhibition assays.', 'id': 'civic:eid3839', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1291 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR E746_S752insV demonstrated increased sensitivity to erlotinib treatment (IC50=25nM), comparable to Ba/F3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=16nM). Sensitivity was determined by IL-3 independent cell survival.', 'id': 'civic:eid4232', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1294 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.', 'id': 'civic:eid4284', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1295 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.', 'id': 'civic:eid4285', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1297 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.', 'id': 'civic:eid4287', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1545 labels=frozenset({'Evidence'}) properties={'description': '3 patients with stage IV non small cell lung adenocarcinoma with G719A mutation were given erlotinib. 1 patient was alive at end of study with progression free survival (PFS) of 27.2 months and overall survival (OS) or 42.4 months, and 2 patients had PFS of 1.3 and 2.1 months, and OS of 9.6 and 2.2 months, and were not alive at study end. In general G719 mutations were reported as having favorable response to tyrosine kinase inhibition in this study, although it was not as high as among exon 19 deletion and L858R mutations.', 'id': 'civic:eid4194', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=1550 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK F1174C co-mutation, demonstrated resistance to crizotinib treatment compared to Ba/F3 cells expressing EML4-ALK fusion. Resistance was determined by assessing cell viability.', 'id': 'civic:eid4430', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1556 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4496', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1591 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing S1986F mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 116 nM), as compared to Ba/F3 cells expressing EZR-ROS1 fusion (IC50: 43 nM). Resistance was determined by assessing cell viability, ROS1, AKT, ERK and S6 phosphorylation.', 'id': 'civic:eid4807', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1630 labels=frozenset({'Evidence'}) properties={'description': 'In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib \\nROS1 resistance mutations were identified in 9/17 (53%) specimens. These included G2032R (41%), D2033N (6%), and S1986F (6%).\\nG2032R is thought to result in steric hindrance with crizotinib,16 while D2033N leads to a reorientation of neighboring residues in front of the ATP binding pocket interacting with crizotinib and loss of a key electrostatic interaction between D2033 and crizotinib. ROS1 S1986F has been purported to confer resistance by impacting the positioning of the glycine-rich loop at the end of the alpha-C helix.', 'id': 'civic:eid7686', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=1703 labels=frozenset({'Evidence'}) properties={'description': 'In a study of 889 non-small cell lung cancer patients, mutations in the EGFR gene was observed in 11.1% of patients (58 of 518 sequenced). Patients with an EGFR mutation were associated with an improved response to erlotinib over placebo treatment (HR:0.10, 95% CI:0.04-0.25, P<0.0001); patients wildtype for EGFR also saw an improved response to erlotinib over placebo treatment (HR:0.78, 95% CI:0.63-0.96, P=0.0185).', 'id': 'civic:eid4195', 'evidence_level': 'civic.evidence_level:B', 'direction': 'supports'}>,\n",
       " <Node id=1721 labels=frozenset({'Evidence'}) properties={'description': 'In a phase 2 study (NCT0093245), a stage IV non-small cell lung cancer patient with acquired crizotinib resistance harbored an EML4-ALK gene rearrangement (a known sensitizing alteration to crizotinib) and an ALK F1174V co-mutation. The ALK F1174V tumor was reported to be refractory to 21-month crizotinib treatment. The patient was treated with erlotinib, 6 cycles of standard chemotherapy, pemetrexed maintenance and then crizotinib..', 'id': 'civic:eid4473', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=1772 labels=frozenset({'Evidence'}) properties={'description': 'In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.', 'id': 'civic:eid267', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1887 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 21 nmol/L and 6 nmol/L, respectively.', 'id': 'civic:eid4197', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1967 labels=frozenset({'Evidence'}) properties={'description': 'A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. Sequencing of circulating cell-free DNA showed EGFR L858R, an acquired novel EGFR M766Q mutation in exon 20, and no evidence of EGFR T790M.', 'id': 'civic:eid7388', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>,\n",
       " <Node id=1970 labels=frozenset({'Evidence'}) properties={'description': 'L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to various EGFR inhibitors.\\nModeling suggested that EGFR M766Q could disrupt osimertinib binding. L858R/M766Q double-mutant cells were 12-fold more resistant to osimertinib, and more than 250-fold more resistant to erlotinib and afatinib, as compared to L858R-mutant cells. In contrast, double-mutant cells remained sensitive to neratinib and poziotinib at clinically relevant doses (IC50, 4.3 and 1.3 nM, respectively).', 'id': 'civic:eid7389', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=1974 labels=frozenset({'Evidence'}) properties={'description': 'L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to various EGFR inhibitors.\\nModeling suggested that EGFR M766Q could disrupt osimertinib binding. L858R/M766Q double-mutant cells were 12-fold more resistant to osimertinib, and more than 250-fold more resistant to erlotinib and afatinib, as compared to L858R-mutant cells. In contrast, double-mutant cells remained sensitive to neratinib and poziotinib at clinically relevant doses (IC50, 4.3 and 1.3 nM, respectively).', 'id': 'civic:eid7390', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>,\n",
       " <Node id=2053 labels=frozenset({'Evidence'}) properties={'description': 'In a pulmonary undifferentiated non-small cell lung cancer patient harboring EGFR S784F mutation, EGFR S784F was reported to be resistant to erlotinib treatment. The patient was initially treated with standard chemotherapy, followed by erlotinib monotherapy, tumor progression was reported after 10 weeks of erlotinib treatment.', 'id': 'civic:eid4469', 'evidence_level': 'civic.evidence_level:C', 'direction': 'supports'}>]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "q.find_evidence_by_label(\"Lung Non-small Cell Carcinoma\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "recovered-cooperative",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "academic-investing",
   "metadata": {},
   "outputs": [],
   "source": [
    "x = q.find_evidence_by_label('afatinib')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "confused-providence",
   "metadata": {},
   "outputs": [],
   "source": [
    "y = q.find_evidence_by_label('afatinib')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "checked-adult",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Node id=3365 labels=frozenset({'Evidence'}) properties={'description': 'In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.', 'id': 'civic:eid2163', 'evidence_level': 'civic.evidence_level:D', 'direction': 'supports'}>"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "y[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "primary-feedback",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['1', '2', '3']"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "['1', '2'] + ['3']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "institutional-brother",
   "metadata": {},
   "outputs": [],
   "source": [
    "e = ['1', '4']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "lyric-quarterly",
   "metadata": {},
   "outputs": [],
   "source": [
    "e += ['3234523']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "arbitrary-kinase",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['1', '4', '3234523']"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "e"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "disturbed-control",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
